Publications in collaboration with researchers from Hospital Ramón y Cajal (26)

2026

  1. Effectiveness and tolerability of dolutegravir/lamivudine in virologically suppressed people with HIV at 96 weeks in a multicentre cohort

    HIV Medicine

  2. Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort

    AIDS (London, England), Vol. 40, Núm. 4, pp. 414-427

2025

  1. A prospective assessment of the efficacy and durability of long-acting cabotegravir and rilpivirine in individuals with HIV in Spain (RELATIVITY study)

    Journal of Antimicrobial Chemotherapy, Vol. 80, Núm. 12, pp. 3438-3451

  2. Are children and adolescents living with HIV in Europe and South Africa at higher risk of SARS-CoV-2 and poor COVID-19 outcomes?

    Epidemiology and Infection, Vol. 153

  3. Health-related quality of life in people with HIV from the multicentre CoRIS cohort in Spain: Associated factors and short-term changes over time

    HIV Medicine, Vol. 26, Núm. 4, pp. 606-620

  4. Increased mortality and morbidity risk in people with early HIV care interruption in Spain

    AIDS, Vol. 39, Núm. 9, pp. 1224-1234

  5. Low-effort HIV training in Spanish primary care: Long-term impact on testing and diagnosis

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 43, Núm. 10, pp. 645-651

  6. Should we measure quality of life among people with HIV? A multicentre survey of physicians' opinions in Spain

    HIV Medicine, Vol. 26, Núm. 2, pp. 308-318

2024

  1. Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain

    AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314

2022

  1. Discovering HIV related information by means of association rules and machine learning

    Scientific Reports, Vol. 12, Núm. 1

2021

  1. COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study

    HIV Medicine, Vol. 22, Núm. 9, pp. 867-876

  2. Late presentation for HIV impairs immunological but not virological response to antiretroviral treatment

    AIDS (London, England), Vol. 35, Núm. 8, pp. 1283-1293

2020

  1. Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: A multicentre cohort study

    AIDS Research and Therapy, Vol. 17, Núm. 1

  2. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study

    The Lancet HIV, Vol. 7, Núm. 8, pp. e565-e573

2018

  1. Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients

    Medicine (United States), Vol. 97, Núm. 38

  2. Low-level viremia is associated with clinical progression in HIV-infected patients receiving antiretroviral treatment

    Journal of Acquired Immune Deficiency Syndromes, Vol. 78, Núm. 3, pp. 329-337

2017

  1. Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach

    PLoS ONE, Vol. 12, Núm. 9

2016

  1. MicroRNA profile in CD8+ T-lymphocytes from HIV-infected individuals: Relationship with antiviral immune response and disease progression

    PLoS ONE, Vol. 11, Núm. 5

2014

  1. Incidence of Hepatitis C Virus (HCV) in a multicenter cohort of HIV-positive patients in Spain 2004-2011: Increasing rates of HCV diagnosis but not of HCV seroconversions

    PLoS ONE, Vol. 9, Núm. 12

  2. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries

    AIDS, Vol. 28, Núm. 16, pp. 2461-2473